| Code | CSB-RA896903MB3HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is a research-grade biosimilar to SHR-1918, designed to specifically target angiopoietin-like protein 3 (ANGPTL3). ANGPTL3 is a liver-secreted glycoprotein that plays a critical role in lipid metabolism by inhibiting lipoprotein lipase and endothelial lipase, thereby regulating plasma triglyceride and HDL cholesterol levels. Elevated ANGPTL3 expression is associated with dyslipidemia, atherosclerotic cardiovascular disease, and metabolic disorders. Loss-of-function mutations in ANGPTL3 have been linked to familial combined hypolipidemia and reduced cardiovascular risk, making this target of significant therapeutic interest.
SHR-1918 (also known as fazirsiran) represents a therapeutic approach to modulate lipid metabolism through ANGPTL3 inhibition. This biosimilar antibody serves as a valuable research tool for investigating ANGPTL3 biology, lipid homeostasis mechanisms, and cardiovascular disease pathogenesis. It enables researchers to explore the functional consequences of ANGPTL3 neutralization in experimental models and to validate findings related to lipid-lowering strategies and metabolic regulation.
There are currently no reviews for this product.